IOVA — Iovance Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $6.67bn
- $6.37bn
- $263.50m
U.S. STOCKS ON THE MOVE-Iovance Biotherapeutics, The9, Guardant Health
Iovance climbs on positive mid-stage data for skin cancer treatment
Brief: Iovance Biotherapeutics Announces Updated Clinical Data For Lifileucel In Combination With Pembrolizumab In Frontline Advanced Melanoma
U.S. RESEARCH ROUNDUP- Akoya Biosciences, Boston Beer Company, Victory Capital Holdings
Iovance Biotherapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Ashland, Oportun Financial, Palomar Holdings
U.S. STOCKS ON THE MOVE-Akero Therapeutics, Vista Outdoor, Sea
U.S. STOCKS ON THE MOVE-Super Micro, Decker, Rumble
Iovance rises as FDA lifts partial clinical hold on lung cancer therapy trial
U.S. STOCKS ON THE MOVE-Avidity, C4 Therapeutics, Avadel Pharma
Iovance rises as FDA lifts partial clinical hold on lung cancer therapy trial
Brief: Iovance Biotherapeutics Says FDA Has Lifted Clinical Hold On The Iov-Lun-202 Registrational Trial
Iovance Biotherapeutics Inc reports results for the quarter ended in December - Earnings Summary
Iovance Biotherapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview
Iovance Biotherapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Iovance Biotherapeutics Says Pricing Of 23 Million Shares Of Its Common Stock At An Offering Price Of $9.15 Per Share
Iovance Biotherapeutics up after skin cancer therapy receives FDA nod
Iovance Biotherapeutics rises after FDA approves skin cancer cell therapy